Article info

Download PDFPDF
Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study

Authors

  1. Correspondence to Dr Dana Chase, Arizona Oncology, Paradise Valley, CA 85253, USA; dana.chase{at}usoncology.com
View Full Text

Citation

Chase D, Huang HQ, Monk BJ, et al
Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study

Publication history

  • Received October 4, 2019
  • Revision received January 18, 2020
  • Accepted February 7, 2020
  • First published February 28, 2020.
Online issue publication 
May 04, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.